Article
Argus II implant in patients presenting a posterior staphyloma
Search Medline for
Authors
-
Laura Cinelli
- Azienda Ospedaliero-Universitaria Careggi SOD Oculistica, Firenze, Italy
-
S. Rizzo
- Azienda Ospedaliero-Universitaria Careggi SOD Oculistica, Firenze, Italy
| Published: | November 30, 2017 |
|---|
Outline
Text
Objective: To evaluate the functional vision and safety of RP patients treated with the Argus® II Retinal Prosthesis System presenting a posterior staphyloma.
Materials and Methods: Optical coherence tomography (OCT) scans of 33 RP patients implanted at the Azienda OspedalieroUniversitaria Pisana (Pisa, Italy) and at the Azienda Ospedaliera Universitaria Careggi (Florence, Italy) were analyzed to find staphyloma. Inclusion criteria was presence of a posterior staphyloma localized in the region of the macula, where the Argus II Retinal Prosthesis System was implanted. A total of 5 patients were included in this study. Functional vision was evaluated with two visual function tests (Square Localization and Direction of Motion) that were designed to evaluate the patient’s ability to locate objects and determine the direction of an object moving in the patient visual field.
Results: The safety profile and the functional vision of Argus II patients presenting a posterior staphyloma are in line with the previously published international clinical trial data.
Discussion: This study supports the safety profile and functional vision of the Argus II System for patients presenting a posterior staphyloma.
Acknowledgment: This work was supported by Second Sight Medical Products.
